Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advancements in the development of multi-target directed ligands for the treatment of Alzheimer’s disease
Naveen Kumar, Vijay Kumar, Piyush Anand, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 61, pp. 116742-116742
Closed Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

A comprehensive review of multi-target directed ligands in the treatment of Alzheimer’s disease
Chandni Pathak, Uma D. Kabra
Bioorganic Chemistry (2024) Vol. 144, pp. 107152-107152
Closed Access | Times Cited: 35
Polypharmacology: promises and new drugs in 2022
Piotr Ryszkiewicz, Barbara Malinowska, Eberhard Schlicker
Pharmacological Reports (2023) Vol. 75, Iss. 4, pp. 755-770
Open Access | Times Cited: 24
New insights into butyrylcholinesterase: Pharmaceutical applications, selective inhibitors and multitarget-directed ligands
Tian‐Yu Sun, Tengfei Zhen, Chrisanta Hamis Harakandi, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116569-116569
Closed Access | Times Cited: 9
Pristine 2-chloroquinoline-based-thiosemicarbazones as multitarget agents against alzheimer's disease: In vitro and in silico studies of monoamine oxidase (MAO) and cholinesterase (ChE) inhibitors
Saquib Jalil, Rabia Basri, Mubashir Aziz, et al.
Journal of Molecular Structure (2024) Vol. 1306, pp. 137841-137841
Closed Access | Times Cited: 8
Targeting Microglia in Neuroinflammation: H3 Receptor Antagonists as a Novel Therapeutic Approach for Alzheimer’s Disease, Parkinson’s Disease, and Autism Spectrum Disorder
Shilu Deepa Thomas, Sabna Abdalla, Nermin Eissa, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 831-831
Open Access | Times Cited: 8
Quinoline–sulfonamides as a multi-targeting neurotherapeutic for cognitive decline:in vitro,in silicostudies and ADME evaluation of monoamine oxidases and cholinesterases inhibitors
Saquib Jalil, Zahid Hussain, Syed Mobashir Ali Abid, et al.
RSC Advances (2024) Vol. 14, Iss. 13, pp. 8905-8920
Open Access | Times Cited: 7
Synthesis and evaluation of multitarget new 2‐aminothiazole derivatives as potential anti‐Alzheimer's agents
Merve Bardakkaya, Burcu Kılıç, Rahşan Ilıkçı Saǧkan, et al.
Archiv der Pharmazie (2023) Vol. 356, Iss. 8
Open Access | Times Cited: 16
Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases
Yu Xiang, Swapna Naik, Liyun Zhao, et al.
Medicinal Research Reviews (2024) Vol. 44, Iss. 4, pp. 1404-1445
Closed Access | Times Cited: 6
In Vitro and In Vivo Investigations of Chromone Derivatives as Potential Multitarget-Directed Ligands: Cognitive Amelioration Utilizing a Scopolamine-Induced Zebrafish Model
Naveen Kumar, Kailash Jangid, Vishal Kumar, et al.
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 14, pp. 2565-2585
Closed Access | Times Cited: 5
In vitro and in vivo Investigations of 4-Substituted 2-Phenylquinazoline derivatives as multipotent ligands for the treatment of Alzheimer’s disease
Vijay Kumar, Kailash Jangid, Vishal Kumar, et al.
Bioorganic Chemistry (2025) Vol. 155, pp. 108126-108126
Closed Access
Multi-target-directed therapeutic strategies for Alzheimer’s disease: controlling amyloid-β aggregation, metal ion homeostasis, and enzyme inhibition
Jeasang Yoo, Jimin Lee, Byeongha Ahn, et al.
Chemical Science (2025)
Open Access
Design, synthesis, molecular docking, DFT analysis, dynamics simulation and cytotoxicity evaluation of coumarin derivatives as acetylcholinesterase (AChE) inhibitors against alzheimer's disease
Shivangi Rai, Vishal Singh, Iqrar Ahmad, et al.
Journal of Molecular Structure (2025), pp. 141436-141436
Closed Access
Multilayered screening for multi-targeted anti-Alzheimer’s and anti-Parkinson’s agents through structure-based pharmacophore modelling, MCDM, docking, molecular dynamics and DFT: a case study of HDAC4 inhibitors
Nikita Chhabra, Balaji Wamanrao Matore, Nisha Lakra, et al.
In Silico Pharmacology (2025) Vol. 13, Iss. 1
Closed Access
Pharmacophore-based virtual screening of the chromone derivatives as potential therapeutic for Alzheimer’s disease
Naveen Kumar, Bharti Devi, Kailash Jangid, et al.
Journal of Biomolecular Structure and Dynamics (2025), pp. 1-15
Closed Access
A study to determine the effect of nano-selenium and thymoquinone on the Nrf2 gene expression in Alzheimer’s disease
Doha El‐Sayed Ellakwa, Laila Ahmed Rashed, Ola Ali, et al.
Future Science OA (2025) Vol. 11, Iss. 1
Open Access
Tanacetum species: Bridging empirical knowledge, phytochemistry, nutritional value, health benefits and clinical evidence
Sohaib Khatib, Mansour Sobeh, Cecilia Faraloni, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 13
Virtual screening and molecular dynamics simulation approach for the identification of potential multi-target directed ligands for the treatment of Alzheimer’s disease
Kailash Jangid, Bharti Devi, Ashrulochan Sahoo, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 1, pp. 509-527
Closed Access | Times Cited: 12
Evidence of disturbed insulin signaling in animal models of Alzheimer’s disease
Suélen Santos Alves, Gabriel Servilha‐Menezes, Letícia Rossi, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 152, pp. 105326-105326
Closed Access | Times Cited: 12
Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects
Zimeng Cheng, Tianyue Han, Jingtong Yao, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116065-116065
Closed Access | Times Cited: 12
Dual-target inhibitors of cholinesterase and GSK-3β to modulate Alzheimer’s disease
Junqiu He, Kin Yip Tam
Drug Discovery Today (2024) Vol. 29, Iss. 4, pp. 103914-103914
Closed Access | Times Cited: 4
Understanding the journey of biopolymeric nanoformulations for oral drug delivery: Conventional to advanced treatment approaches
Ameya Sharma, Nitin Jangra, Divya Dheer, et al.
European Polymer Journal (2024) Vol. 218, pp. 113338-113338
Closed Access | Times Cited: 4
A multi-target directed ligands strategy for the treatment of Alzheimer's disease: Dimethyl fumarate plus Tranilast modified Dithiocarbate as AChE inhibitor and Nrf2 activator
Jie Guo, Maojun Cheng, Peng Liu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 242, pp. 114630-114630
Closed Access | Times Cited: 21
A Review of the Recent Advances in Alzheimer’s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics
Rima Hajjo, Dima A. Sabbah, Osama H. Abusara, et al.
Diagnostics (2022) Vol. 12, Iss. 12, pp. 2975-2975
Open Access | Times Cited: 21
Synthesis, characterization, molecular docking and molecular dynamics simulations of novel 2,5-disubstituted-1,3,4-thiadiazole derivatives as potential cholinesterase/monoamine oxidase dual inhibitors for Alzheimer’s disease
Amal A. AL-Sharabi, Asaf Evrim Evren, Begüm Nurpelin Sağlık, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 23, pp. 13023-13041
Closed Access | Times Cited: 10
The improvement potential of camel milk whey as a natural remedy in comparison with Rivastigmine chitosan-loaded nanoparticles in aluminum chloride induced Alzheimer-like disease in rats
Dina E. ElMosbah, Marwa S. Khattab, Marwa Ibrahim, et al.
Egyptian Journal of Veterinary Science (2024) Vol. 55, Iss. 5, pp. 1435-1446
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top